UCB S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jean-Christophe Tellier
- Full Time Employees
- 10,117
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Allée de la Recherche, 60 Brussels BU Belgium 1070
- IPO Date
- Aug 26, 2008
- Website
- ucb.com
- Similar Companies
- Business
- UCB SA is a global biopharmaceutical company focused on developing and commercializing innovative medicines for immunology, neurology, and dermatology disorders. The company offers a portfolio of branded products including Cimzia (certolizumab pegol) for inflammatory autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and non-radiographic axial spondyloarthritis; Evenity (romosozumab) for osteoporosis in postmenopausal women at high risk for fracture; Briviact (brivaracetam) for partial-onset seizures in epilepsy patients; Nayzilam (midazolam) nasal spray for acute treatment of seizure clusters; and Vyvey (eptinezumab) for migraine prevention, along with other therapies like Nozinan and Zeposia. UCB SA operates in over 40 countries with manufacturing facilities in Europe, North America, and Asia, targeting patients, healthcare providers, and partners in the biopharma sector. Founded in 1928 and headquartered in Brussels, Belgium, the company maintains subsidiaries worldwide and continues to advance its pipeline through research in severe diseases. In recent developments, UCB completed the acquisition of Zogenix in 2023 to bolster its neurology portfolio with Xcopri (cenobamate) for epilepsy; launched Vyvey in multiple European markets in 2022-2023 for migraine; reported positive Phase 3 results for rozanolixizumab in myasthenia gravis in 2023 leading to regulatory filings; and announced a strategic partnership with Roche in 2024 for bispecific antibody development in immunology.
Company News
United Community Banks (UCB) Reports Next Week: Wall Street Expects Earnings Growth
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Moderate Buy” from Brokerages
Why United Community Banks (UCB) is a Great Dividend Stock Right Now
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UCB (UCBJY) Upgraded to Buy: Here's Why
Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio
United Community Banks, Inc. (UCB) Discusses Completion of Strategic Initiatives and Sale of Navitas to Strengthen Financial Position Transcript
United Community Banks (UCB) is a Top Dividend Stock Right Now: Should You Buy?
United Community Banks (UCB) Could Be a Great Choice
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript
UCB shares fall despite guidance upgrade as investors question earnings quality
United Community Banks, Inc. (UCB) Q2 2026 Earnings Call Transcript
United Community Banks (UCB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
United Community Banks (UCB) Q2 Earnings and Revenues Miss Estimates
UCB: From Rebuild To Re-Rating (Initiating Buy)
United Community Banks (UCB) Earnings Expected to Grow: Should You Buy?
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
United Community Banks, Inc. (UCB) M&A Call Transcript